Elekta stock highlights long term Unity study results

Published on 10/04/2026 at 21:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Elekta stock stood at SEK 51.60 on October 2, 2026, while a 123-patient Unity study reported 37.4 percent survival at two years. Q1 margins improved.

Isometrische 3D-Grafik einer Wertschöpfungskette von Labor bis Patientenbett — Isometrische 3D-Illustration der Wertschöpfungskette veranschaulicht den Weg von Forschung bis Patientenversorgung bei Elekta AB SE0000163628, Illustration mit AI erstellt.

Elekta stock (ISIN SE0000163628) closed at SEK 51.60 on Nasdaq Stockholm on October 2, 2026, down 0.86 percent from the previous close. The company is pairing that market level with new clinical data for its Unity MR-Linac, as Elekta reported on September 28, 2026. For investors, the data add a clinical proof point to a business still working through uneven demand.

Unity study delivers measurable outcomes

The study followed 123 patients with localized pancreatic cancer who received MR-guided adaptive radiotherapy between May 2020 and December 2024. After a median follow-up of more than two years, overall survival was 37.4 percent at two years and 26.3 percent at three years, while 76.8 percent of patients remained free from local tumor progression at both time points, according to Elekta.

The figures matter because Unity adapts treatment to the patient anatomy visible during each session. Patients received five treatments over two weeks, giving the platform a quantified clinical use case rather than only a product launch narrative.

Margins offset a weaker top line

Elekta's Q1 FY2026/27 revenue fell 2 percent in constant currency to SEK 3.536 billion, while adjusted gross margin increased to 42.6 percent from 37.0 percent a year earlier. Adjusted EBIT reached SEK 395 million, equal to an 11.2 percent margin, according to Investing.com.

Net income rose to SEK 261 million from SEK 106 million in Q1 FY2025/26, while reported EPS increased to SEK 0.69 from SEK 0.28. Management maintained fiscal 2026/27 guidance for constant-currency sales growth of 2 percent to 4 percent and an adjusted EBIT margin of 12.5 percent to 13.5 percent, as Investing.com reported.

Consensus target stays above the stock

MarketScreener lists a Hold consensus from 14 analysts, with an average 12-month target of SEK 59.69, a high target of SEK 100.00 and a low target of SEK 41.00. The average target lies 15.7 percent above the October 2 closing price, leaving the market view split between margin recovery and execution risks.

Elekta's next scheduled report is November 25, 2026. Until then, the key test is whether improved profitability can develop alongside renewed revenue growth.

Elekta stock stays below its yearly high

Elekta stock closed at SEK 51.60 on October 2, 2026, compared with a 52-week high of SEK 66.70 and a 52-week low of SEK 41.86. The closing price was 22.6 percent below the yearly high.